Xlife Sciences AG Ordinary Shares XLS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- CHF 9.90
- Day Range
- CHF 9.54–9.90
- 52-Week Range
- CHF 9.34–26.80
- Bid/Ask
- CHF 9.36 / CHF 9.80
- Shares Outstanding
- 5.77M
- Market Cap
- CHF 56.52M
- Volume/Avg
- 4,487 / 4,547
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 151.08
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Xlife Sciences AG is a Swiss incubator and accelerator company focused on the value development and commercialization of research projects from universities and other life science research institutions, to provide solutions for high-unmet medical needs. It holds majority or minority interests in project companies that are engaged in areas of the company's reportable segments, which include Technology platforms, Medical Technology, Biotechnology/Therapeutics, and Artificial Intelligence/Digital Medicine.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 17
- Website
- https://www.xlifesciences.ch
Valuation
|
Metric
|
XLS
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.46 |
Price/Sales | 151.08 |
Price/Cash Flow | — |
Price/Earnings
XLS
Financial Strength
|
Metric
|
XLS
|
|---|---|
Quick Ratio | 0.15 |
Current Ratio | 0.15 |
Interest Coverage | −369.65 |
Quick Ratio
XLS
Profitability
|
Metric
|
XLS
|
|---|---|
Return on Assets (Normalized) | −6.96% |
Return on Equity (Normalized) | −13.66% |
Return on Invested Capital (Normalized) | −8.43% |
Return on Assets
XLS
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|?%>yXH | LOCK|NKBgz | $129B | |||
| Moderna Inc
MRNA
| LOCK|>nlxfyk | LOCK|g< | $90B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|DwKtSQ | LOCK|Xg$? | $77B | |||
| argenx SE ADR
ARGX
| LOCK|m?!<&r | LOCK|^tt | $51B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|>g#<$@ | LOCK|!QY | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|V@qWRr$ | LOCK|WDyR | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|V?$f@bC^ | LOCK|D<>h# | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|g!Zhwmz | LOCK|&Tb | $24B | |||
| Incyte Corp
INCY
| LOCK|&&CLR&q | LOCK|ql | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|^<RkCn | LOCK|hz> | $14B |
United States